Loading…
Lineage Cell Therapeutics, Inc. is projected to rise to $1.53 by 2027, a +18% move from its current price of $1.30. LCTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.26 | $1.30 | $1.34 | -0.05% |
| May 30 | $1.25 | $1.30 | $1.35 | -0.09% |
| May 31 | $1.24 | $1.30 | $1.36 | -0.14% |
| Jun 1 | $1.23 | $1.30 | $1.37 | -0.19% |
| Jun 2 | $1.22 | $1.30 | $1.38 | -0.23% |
| Jun 3 | $1.21 | $1.30 | $1.39 | -0.28% |
| Jun 4 | $1.20 | $1.30 | $1.40 | -0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.20 | $1.30 | $1.40 | -0.32% |
| Week 2 | $1.16 | $1.29 | $1.43 | -0.65% |
| Week 3 | $1.13 | $1.29 | $1.46 | -0.97% |
| Week 4 | $1.11 | $1.28 | $1.49 | -1.29% |
| Week 5 | $1.08 | $1.28 | $1.51 | -1.61% |
| Week 6 | $1.06 | $1.27 | $1.53 | -1.93% |
| Week 7 | $1.04 | $1.27 | $1.55 | -2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell replacement therapies to treat serious medical conditions in the United States and internationally. Its product slate includes OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy in Phase 2a for the treatment of age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy in Phase 1/2a multicenter trials for cervical spinal cord injuries; and ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant in preclinical development for sensorineural hearing loss.
Other programs include PNC1 in preclinical development for vision loss due to photoreceptor dysfunction, along with RND1, an hypoimmune induced pluripotent stem cell line, ILT1 for Type 1 Diabetes, and LCT-CON for additional retinal, neurological, ophthalmologic, metabolic, and oncology indications. The company has collaborations with William Demant Invest for ReSonance and with Factor Bioscience for a genetically engineered iPSC line. Formerly BioTime, Inc., the company changed its name to Lineage Cell Therapeutics, Inc.
in August 2019 and was incorporated in 1990. It is headquartered in Carlsbad, California.
Lineage Cell Therapeutics, Inc. (LCTX) operates in the Healthcare sector as a clinical-stage biotech focused on cell replacement therapies. Its current price is $1.30 with a market capitalization of $324.09M and it is ranked 3447.
The stock is currently labeled BEARISH by its near-term technical backdrop, with an RSI of 40 and moving averages indicating a headwind against sustained advances. The 50-day simple moving average sits at $1.48 and the 200-day simple moving average at $1.59, placing the stock below both averages and signaling potential ongoing pressure. In the near term, a defined support is seen at $1.20 and a resistance at $1.71, with the 30-day trading range spanning $1.07 to $1.58.
Looking farther ahead, the forecast array shows a path from a neutral stance in 2026 through increasingly bullish outcomes, with average prices rising and long-term ROI expanding to multi-year highs by 2050.
A major floor 31.3% below — a decisive break under it would weaken the trend.
The nearest floor, 7.7% below — buyers have tended to step in here.
The nearest ceiling, 31.5% above — a clean break opens room to run.
A major ceiling 50.8% above — clearing it would confirm fresh momentum.
Key LCTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LCTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.30 | Buy | $1.29 | Buy |
| MA 10 | $1.28 | Buy | $1.30 | Sell |
| MA 20 | $1.35 | Sell | $1.35 | Sell |
| MA 50 | $1.47 | Sell | $1.46 | Sell |
| MA 100 | $1.60 | Sell | $1.53 | Sell |
| MA 200 | $1.59 | Sell | $1.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.29 | Neutral |
| Stoch RSI (14) | 92.17 | Sell |
| CCI (20) | -42.43 | Neutral |
| Williams %R (14) | -41.18 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -5.11 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 58.82 | Neutral |
| TRIX (15) | -0.72 | Sell |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 50.76 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 1.31 | Sell |
| ADX (14) | 22.49 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is mixed but leanings are bearish. RSI is at 40, which aligns with a cautious or negative momentum reading as price trades below key moving averages. Price is below the 50-day SMA of $1.48 and the 200-day SMA of $1.59, indicating relative weakness versus these benchmarks.
Near-term support sits at $1.20 and resistance at $1.71, with the 30-day range from $1.07 to $1.58 providing a band within which the stock could consolidate.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.20 | $1.30 | $1.71 | 0% | Neutral | |
| $1.21 | $1.53 | $2.05 | +18% | Neutral | |
| $1.45 | $1.88 | $2.62 | +45% | Bullish | |
| $1.62 | $2.15 | $3.08 | +66% | Bullish | |
| $1.69 | $2.30 | $3.37 | +77% | Bullish | |
| $1.61 | $2.22 | $3.33 | +71% | Bullish | |
| $1.69 | $2.39 | $3.65 | +84% | Bullish | |
| $1.88 | $2.70 | $4.19 | +108% | Bullish | |
| $2.10 | $3.06 | $4.83 | +135% | Bullish | |
| $2.44 | $3.61 | $5.78 | +178% | Bullish | |
| $2.90 | $4.59 | $7.84 | +253% | Bullish | |
| $4.92 | $8.79 | $16.43 | +576% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.20 | $1.30 | $1.53 | +0.00% |
| June 2026 | $1.08 | $1.26 | $1.52 | -2.72% |
| July 2026 | $1.05 | $1.25 | $1.52 | -1.46% |
| August 2026 | $1.09 | $1.30 | $1.60 | +3.96% |
| September 2026 | $1.10 | $1.32 | $1.64 | +1.66% |
| October 2026 | $1.07 | $1.29 | $1.61 | -2.19% |
| November 2026 | $1.07 | $1.30 | $1.64 | +1.09% |
| December 2026 | $1.10 | $1.34 | $1.71 | +3.19% |
Click any year to see its month-by-month LCTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect LCTX to range from $1.20 to $1.71 through 2026. The $1.30 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The LCTX price prediction for 2027 points to an average of $1.53 (low $1.21, high $2.05) — a potential gain of +18% on today's $1.30. A consolidation phase looks the most probable path here.
In 2028, LCTX is projected to trade between $1.45 and $2.62, averaging $1.88 — a potential gain of +45% from today's $1.30. That is up +23% on the projected 2027 average. Momentum favours further upside here.
Lineage Cell Therapeutics, Inc.'s 2029 outlook centres on $2.15, within a $1.62 to $3.08 range. That is up +14% on the projected 2028 average. That marks a +66% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, LCTX could reach as high as $3.37, with a base case around $2.30 and support toward $1.69 — roughly +77% from $1.30. Momentum favours further upside here.
Expect LCTX to range from $1.61 to $3.33 through 2031. The $2.22 average target implies a +71% move from current prices. That is -3% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The LCTX price prediction for 2032 points to an average of $2.39 (low $1.69, high $3.65) — a potential gain of +84% on today's $1.30. Momentum favours further upside here.
In 2033, LCTX is projected to trade between $1.88 and $4.19, averaging $2.70 — a potential gain of +108% from today's $1.30. That is up +13% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Lineage Cell Therapeutics, Inc.'s 2034 outlook centres on $3.06, within a $2.10 to $4.83 range. That is up +13% on the projected 2033 average. That marks a +135% change versus current levels. Momentum favours further upside here.
By 2035, LCTX could reach as high as $5.78, with a base case around $3.61 and support toward $2.44 — roughly +178% from $1.30. Buyers look set to stay in control over this stretch.
Expect LCTX to range from $2.90 to $7.84 through 2040. The $4.59 average target implies a +253% move from current prices. That is up +27% on the projected 2035 average. Momentum favours further upside here.
The LCTX price prediction for 2050 points to an average of $8.79 (low $4.92, high $16.43) — a potential gain of +576% on today's $1.30. Buyers look set to stay in control over this stretch.
Investing $1,000 in LCTX today (≈ 769.230769 LCTX) could be worth
$6,759.96
+$5,759.96 (+576%) by 2050 · US Dollar
Based on the average projected LCTX price of $8.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LCTXwould be worth at today's price.
$1,000 invested in LCTX on May 27, 2025 (≈ 1,470.58822 LCTX) would be worth
$1,911.76
+$911.76 (+91.2%) today · 1.91× · US Dollar
Based on a LCTX entry price of $0.68 vs. today's $1.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.29 | $1,007.75 | +0.8% |
| 1 month ago | $1.55 | $838.71 | -16.1% |
| 3 months ago | $1.96 | $663.27 | -33.7% |
| 6 months ago | $1.76 | $738.64 | -26.1% |
| 1 year ago | $0.68 | $1,911.76 | +91.2% |
| All time (5.0y) ago | $3 | $433.33 | -56.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LCTX forecast.
Our base-case forecast reaches $2.60 around 2033.
Implied market cap at $2.60: $648.18M
The multi-year forecast shows a bullish trajectory after 2027, with rising average prices and improving ROI across the horizon. The 2026 forecast is an average of $1.30 with a min $1.20 and max $1.71 and an ROI of 0%, signaling a neutral start. From 2027 onward, the path strengthens: 2027 avg $1.51, 2028 avg $1.90, 2029 avg $2.16, and 2030 avg $2.29, with ROIs of 16.5%, 46.5%, 66.5%, and 76% respectively, all labeled BULLISH from 2028 onward.
By 2035 the forecast shows an avg of $3.61 with a max of $5.88 and ROI of 177.3%, continuing to rise through 2040 (avg $4.59, max $7.98, ROI 252.7%) and into 2050 (avg $8.68, max $16.59, ROI 567.4%). These projections carry a BULLISH sentiment for the later years, reflecting potential long-term upside alongside the inherent uncertainties of biotech development.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $2.29, with a min of $1.66 and a max of $3.40. The ROI for 2030 is projected at 76% and the sentiment is BULLISH.
The forecast depicts a bullish trajectory from 2028 onward, with rising averages and higher ROI through 2030, 2040, and 2050. However, these are estimates and not guarantees, and actual results can vary.
Yes. The forecast lists a max of $5.88 in 2035 and $7.98 in 2040, indicating potential for prices above $5 within the forecast horizon.
Current price is $1.30 and market cap is $324.09M, with a rank of 3447.
Bearish sentiment with RSI at 40. The price trades below the 50-day SMA ($1.48) and the 200-day SMA ($1.59). Support is at $1.20 and resistance at $1.71, while the 30-day range is $1.07–$1.58.
Lineage Cell Therapeutics, Inc. Community Discussion
0Share your Lineage Cell Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.